BLES Biochemicals Inc. (B) BLES Biochemicals Inc. (B)

BLES Biochemicals Inc. (B‪)‬

9B03M027

    • 0,99 €
    • 0,99 €

Description de l’éditeur

This is a supplement to BLES Biochemicals Inc. (A), product 9B03M026. The (A) case explores the growth options available to a new biotech company with a revolutionary drug for premature infants. There seems to be a significant potential for international growth. The (B) case takes place six months later when the president of the company obtains new data concerning market size projections, technological advances and competitor actions that require him to reconsider the company's strategic positioning and plans for international expansion.

GENRE
Entreprise et management
SORTIE
2003
25 septembre
LANGUE
EN
Anglais
LONGUEUR
3
Pages
ÉDITIONS
Richard Ivey School of Business Foundation
DÉTAILS DU FOURNISSEUR
Ivey Business School Foundation Foundation
TAILLE
363,1
Ko
Discovery Labs Updates on Surfaxin Marketing Authorization Discovery Labs Updates on Surfaxin Marketing Authorization
2011
Pharma Technologies Inc. Pharma Technologies Inc.
2004
Delex Therapeutics, Inc. Delex Therapeutics, Inc.
2003
Molecularizing Biology and Medicine Molecularizing Biology and Medicine
2003
Value Creation in the Pharmaceutical Industry Value Creation in the Pharmaceutical Industry
2016
Biovail Corporation (A) Biovail Corporation (A)
2004
Virtek Vision International Inc. Virtek Vision International Inc.
2001
Salesphere.com: Building an Internet Start-up Company in Hong Kong Salesphere.com: Building an Internet Start-up Company in Hong Kong
2001
Silent Witness Enterprises Ltd. Silent Witness Enterprises Ltd.
2001
MessageTech, Inc. MessageTech, Inc.
2001
Industry Note: Biotechnology in Canada Industry Note: Biotechnology in Canada
2002
Spotnik Communications (B) - The Partnering Decision Spotnik Communications (B) - The Partnering Decision
2003